NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

Recruiting now · Not applicable

Conditions studied: Locally Advanced Pancreatic Cancer

In brief

The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.

Key facts

Study ID

NCT06494514

Run by

Du Juan

People needed

40

Starts

2024-04-01

Expected to finish

2027-04-01

Last updated by the study team

2024-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed pancreatic cancer;
• ECOG performance no more than 2;
• Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;
• No previous anti-tumor therapy；
• Able and willing to provide a written informed consent;

You may not qualify if…

• 1. Prior anti-tumor therapy of any kind; 2. Severe infection (>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.

Where it is running

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — Nanjing, Jiangsu, China (enrolling)
• FirstNanjingMU — Nanjing, Jiangsu, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.